Advertisement
Screener

BRISTOL-MYERS SQUIBB COMPANY (BMY) Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax

2.2 / 5 stars · 48/110 Roast Me

BRISTOL-MYERS SQUIBB COMPANY Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax

BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax of -$2.00 million for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-10-25.

Discontinued › Expense Statement › Income Tax

us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax · last filed 2018-10-25

  • BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for the quarter ending 2018-09-30 was -$2.00M, a 133.33% decline year-over-year.
  • BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for the quarter ending 2018-06-30 was $1.00M.
  • BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for the quarter ending 2018-03-31 was $7.00M.
  • BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for the quarter ending 2017-12-31 was $8.00M.
  • BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for fiscal 2017 was $8.00M, a 166.67% increase from fiscal 2016.
  • BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for fiscal 2016 was $3.00M.
  • BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for fiscal 2015 was -$42.00M.
  • BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for fiscal 2014 was -$16.00M.
Period endOther Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 3 monthOther Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 6 monthOther Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 9 monthOther Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 12 month
2018-09-30-$2.00M
10-Q · filed 2018-10-25
-$1.00M
derived: sum of 2 quarters · filed 2018-10-25
$6.00M
10-Q · filed 2018-10-25
$14.00M
derived: sum of 4 quarters · filed 2018-10-25
2018-06-30$1.00M
10-Q · filed 2018-07-26
$8.00M
10-Q · filed 2018-07-26
$16.00M
derived: sum of 3 quarters · filed 2018-07-26
$22.00M
derived: sum of 4 quarters · filed 2018-10-25
2018-03-31$7.00M
10-Q · filed 2018-04-26
$15.00M
derived: sum of 2 quarters · filed 2018-04-26
$21.00M
derived: sum of 3 quarters · filed 2018-10-25
$19.00M
derived: sum of 4 quarters · filed 2018-10-25
2017-12-31$8.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13
$14.00M
derived: sum of 2 quarters · filed 2018-10-25
$12.00M
derived: sum of 3 quarters · filed 2018-10-25
$8.00M
10-K · filed 2018-02-13
2017-09-30$6.00M
10-Q · filed 2018-10-25
$4.00M
derived: sum of 2 quarters · filed 2018-10-25
$0.00
10-Q · filed 2018-10-25
-$2.00M
derived: sum of 4 quarters · filed 2018-10-25
2017-06-30-$2.00M
10-Q · filed 2018-07-26
-$6.00M
10-Q · filed 2018-07-26
-$8.00M
derived: sum of 3 quarters · filed 2018-07-26
-$1.00M
derived: sum of 4 quarters · filed 2018-07-26
2017-03-31-$4.00M
10-Q · filed 2018-04-26
-$6.00M
derived: sum of 2 quarters · filed 2018-04-26
$1.00M
derived: sum of 3 quarters · filed 2018-04-26
$1.00M
derived: sum of 4 quarters · filed 2018-04-26
2016-12-31-$2.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13
$5.00M
derived: sum of 2 quarters · filed 2018-02-13
$5.00M
derived: sum of 3 quarters · filed 2018-02-13
$3.00M
10-K · filed 2018-02-13
2016-09-30$7.00M
10-Q · filed 2017-10-26
$7.00M
derived: sum of 2 quarters · filed 2017-10-26
$5.00M
10-Q · filed 2017-10-26
-$4.00M
derived: sum of 4 quarters · filed 2018-02-13
2016-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-27
-$2.00M
10-Q · filed 2017-07-27
-$11.00M
derived: sum of 3 quarters · filed 2018-02-13
-$24.00M
derived: sum of 4 quarters · filed 2018-02-13
2016-03-31-$2.00M
10-Q · filed 2017-04-27
-$11.00M
derived: sum of 2 quarters · filed 2018-02-13
-$24.00M
derived: sum of 3 quarters · filed 2018-02-13
-$35.00M
derived: sum of 4 quarters · filed 2018-02-13
2015-12-31-$9.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13
-$22.00M
derived: sum of 2 quarters · filed 2018-02-13
-$33.00M
derived: sum of 3 quarters · filed 2018-02-13
-$42.00M
10-K · filed 2018-02-13
2015-09-30-$13.00M
10-Q · filed 2016-10-27
-$24.00M
derived: sum of 2 quarters · filed 2016-10-27
-$33.00M
10-Q · filed 2016-10-27
-$44.00M
derived: sum of 4 quarters · filed 2017-02-21
2015-06-30-$11.00M
10-Q · filed 2016-07-28
-$20.00M
10-Q · filed 2016-07-28
-$31.00M
derived: sum of 3 quarters · filed 2017-02-21
-$36.00M
derived: sum of 4 quarters · filed 2017-02-21
2015-03-31-$9.00M
10-Q · filed 2016-04-28
-$20.00M
derived: sum of 2 quarters · filed 2017-02-21
-$25.00M
derived: sum of 3 quarters · filed 2017-02-21
-$23.00M
derived: sum of 4 quarters · filed 2017-02-21
2014-12-31-$11.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21
-$16.00M
derived: sum of 2 quarters · filed 2017-02-21
-$14.00M
derived: sum of 3 quarters · filed 2017-02-21
-$16.00M
10-K · filed 2017-02-21
2014-09-30-$5.00M
10-Q · filed 2015-10-27
-$3.00M
derived: sum of 2 quarters · filed 2015-10-27
-$5.00M
10-Q · filed 2015-10-27
-$10.00M
derived: sum of 4 quarters · filed 2016-02-12
2014-06-30$2.00M
10-Q · filed 2015-07-23
$0.00
derived: sum of 2 quarters · filed 2015-07-23
-$5.00M
derived: sum of 3 quarters · filed 2016-02-12
-$6.00M
derived: sum of 4 quarters · filed 2016-02-12
2014-03-31-$2.00M
10-Q · filed 2015-04-28
-$7.00M
derived: sum of 2 quarters · filed 2016-02-12
-$8.00M
derived: sum of 3 quarters · filed 2016-02-12
-$19.00M
derived: sum of 4 quarters · filed 2016-02-12
2013-12-31-$5.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12
-$6.00M
derived: sum of 2 quarters · filed 2016-02-12
-$17.00M
derived: sum of 3 quarters · filed 2016-02-12
-$22.00M
10-K · filed 2016-02-12
2013-09-30-$1.00M
10-Q · filed 2014-10-24
-$12.00M
derived: sum of 2 quarters · filed 2014-10-24
-$17.00M
10-Q · filed 2014-10-24
-$22.00M
derived: sum of 4 quarters · filed 2015-02-13
2013-06-30-$11.00M
10-Q · filed 2014-07-24
-$16.00M
10-Q · filed 2014-07-24
-$21.00M
derived: sum of 3 quarters · filed 2015-02-13
-$30.00M
derived: sum of 4 quarters · filed 2015-02-13
2013-03-31-$5.00M
10-Q · filed 2014-04-29
-$10.00M
derived: sum of 2 quarters · filed 2015-02-13
-$19.00M
derived: sum of 3 quarters · filed 2015-02-13
2012-12-31-$5.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13
-$14.00M
derived: sum of 2 quarters · filed 2015-02-13
-$20.00M
10-K · filed 2015-02-13
2012-09-30-$9.00M
10-Q · filed 2013-10-23
-$15.00M
10-Q · filed 2013-10-23
2011-12-31$20.00M
10-K · filed 2014-02-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
PFIZER INC (PFE)United States$162.042B31.94
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64